See more : freenet AG (FNTN.HM) Income Statement Analysis – Financial Results
Complete financial analysis of MeiraGTx Holdings plc (MGTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MeiraGTx Holdings plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Yum! Brands, Inc. (YUM) Income Statement Analysis – Financial Results
- Zodiac Energy Limited (ZODIAC.BO) Income Statement Analysis – Financial Results
- Altavoz Entertainment, Inc. (AVOZ) Income Statement Analysis – Financial Results
- EssilorLuxottica Société anonyme (ESLOF) Income Statement Analysis – Financial Results
- Columbia Banking System, Inc. (COLB) Income Statement Analysis – Financial Results
MeiraGTx Holdings plc (MGTX)
About MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.02M | 15.92M | 37.70M | 15.56M | 13.29M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 8.72M | 7.87M | 0.00 | 0.00 | 2.05M | 679.18K | 243.08K |
| Gross Profit | 14.02M | 7.20M | 29.83M | 15.56M | 13.29M | -2.05M | -679.18K | -243.08K |
| Gross Profit Ratio | 100.00% | 45.21% | 79.12% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 103.79M | 85.73M | 67.13M | 33.91M | 24.88M | 33.62M | 22.36M | 14.04M |
| General & Administrative | 47.29M | 46.55M | 43.77M | 44.21M | 46.68M | 44.48M | 9.33M | 6.03M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.29M | 46.55M | 43.77M | 44.21M | 46.68M | 44.48M | 9.33M | 6.03M |
| Other Expenses | 0.00 | 361.00K | -434.00K | 0.00 | 0.00 | 83.08K | -553.50K | 0.00 |
| Operating Expenses | 151.08M | 132.28M | 110.89M | 78.12M | 71.56M | 78.10M | 31.68M | 20.06M |
| Cost & Expenses | 151.08M | 132.28M | 110.89M | 78.12M | 71.56M | 78.10M | 31.68M | 20.06M |
| Interest Income | 2.27M | 777.00K | 212.00K | 1.28M | 370.60K | 53.41K | 26.07K | 32.07K |
| Interest Expense | 13.25M | 4.95M | 288.00K | 139.20K | 48.61K | 33.43K | 42.86K | 25.44K |
| Depreciation & Amortization | 13.73M | 8.72M | 7.87M | 4.17M | 3.35M | 2.05M | 679.18K | 243.08K |
| EBITDA | -57.05M | -115.95M | -71.40M | -53.68M | -51.35M | -78.10M | -31.01M | -19.82M |
| EBITDA Ratio | -407.02% | -725.99% | -193.58% | -393.75% | -435.58% | 0.00% | 0.00% | 0.00% |
| Operating Income | -137.06M | -116.36M | -73.19M | -62.55M | -58.27M | -78.10M | -31.68M | -20.06M |
| Operating Income Ratio | -977.82% | -730.87% | -194.14% | -401.94% | -438.37% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 53.03M | -13.26M | -6.37M | 4.56M | 3.52M | -5.24M | 640.19K | 272.17K |
| Income Before Tax | -84.03M | -129.62M | -79.56M | -57.99M | -54.75M | -83.34M | -31.04M | -19.79M |
| Income Before Tax Ratio | -599.46% | -814.16% | -211.03% | -372.63% | -411.87% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 13.26M | -7.59M | -4.03M | -2.19M | -474.39K | -510.64K | -280.44K |
| Net Income | -84.03M | -142.88M | -71.98M | -53.96M | -52.56M | -82.87M | -31.04M | -19.49M |
| Net Income Ratio | -599.46% | -897.46% | -190.91% | -346.72% | -395.40% | 0.00% | 0.00% | 0.00% |
| EPS | -1.49 | -3.16 | -1.63 | -1.43 | -1.58 | -4.37 | -3.62 | -1.01 |
| EPS Diluted | -1.49 | -3.16 | -1.63 | -1.43 | -1.58 | -4.37 | -3.62 | -1.01 |
| Weighted Avg Shares Out | 56.49M | 45.18M | 44.14M | 37.72M | 33.16M | 18.95M | 8.57M | 19.24M |
| Weighted Avg Shares Out (Dil) | 56.49M | 45.18M | 44.14M | 37.72M | 33.16M | 18.95M | 8.57M | 19.24M |
Why MeiraGTx Holdings Stock Is Down Today
MeiraGTx Announces Pricing of Public Offering of Ordinary Shares
MeiraGTx Announces Proposed Public Offering of Ordinary Shares
MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment
MeiraGTx to Present at the Barclays Gene Editing & Gene Therapy Summit
MeiraGTx Reports Third Quarter 2020 Financial Results
MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at AAO 2020 Virtual Meeting
MeiraGTx Is A Buy With Multiple Near-Term Catalysts As The Stock Is Weighed Down By Negative Sentiment
MeiraGTx Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
Head to Head Review: MeiraGTx (NASDAQ:MGTX) vs. Mymetics (NASDAQ:MYMX)
Source: https://incomestatements.info
Category: Stock Reports